Skip to main content
FDA OKs Pfizer's biosimilar Retacrit for anemia

The FDA approved Pfizer's anemia drug Retacrit, or epoetin alfa-epbx, a biosimilar version of Amgen's Epogen and Johnson & Johnson's Procrit. The approval allows the use of Retacrit to treat incidents of red blood cell counts dropping due to chemotherapy, chronic kidney disease or the use of zidovudine in HIV patients, and as a preventive measure to avoid the need for red blood cell transfusions before and after surgery.

Full Story: